The expanding role of fluoroquinolones

American Journal of Medicine

Volumn 113, Issue 1 SUPPL. 1, 2002, Pages 45-54

  Schaeffer, Anthony J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; CEFTRIAXONE; CIPROFLOXACIN; CISAPRIDE; COTRIMOXAZOLE; ENOXACIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; METHYLXANTHINE; NEUROLEPTIC AGENT; NORFLOXACIN; OFLOXACIN; PROCAINAMIDE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOTALOL; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; GEOGRAPHY; HALLUCINATION; HEADACHE; HUMAN; HYPOKALEMIA; NAUSEA; PRIORITY JOURNAL; PSYCHOSIS; PYELONEPHRITIS; RESTLESSNESS; REVIEW; RISK FACTOR; SEIZURE; SIDE EFFECT; SKIN DISEASE; TREMOR; URINARY TRACT INFECTION; VAGINITIS; VERTIGO;

EID: 0037043299     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01059-8     Document Type: Article

References (69)

1. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: A nationwide analysis
2. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women
3. The safety profile of fluoroquinolones
4. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections
5. Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999
6. Type II Topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: Role of target enzyme in mechanism of fluoroquinolone resistance
7. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?
8. Activity of levofloxacin and ciprofloxacin against urinary pathogens
9. Fluoroquinolones in paediatrics
10. Safety of long-term ciprofloxacin: Data analysis of controlled clinical trials and review
11. Efficacy and tolerability of twice-daily ciprofloxacin 750 mg in the treatment of patients with acute exacerbations of chronic bronchitis and pneumonia
12. Safety of oral ciprofloxacin. An update based on clinical trial results
13. Hypersensitivity and anaphylactoid reactions to ciprofloxacin
14. Ciprofloxacin: An updated review of its pharmacology, therapeutic efficacy and tolerability
15. Possible interaction of ciprofloxacin and cyclosporin A
16. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporin A
17. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women: Ciprofloxacin Urinary Tract Infection Group
18. Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women
19. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: A randomized trial
20. Gatifloxacin, an advanced 8-methoxy fluoroquinolone
21. Gatifloxacin
22. Bactericidal activity of gatifloxacin (AM-1155) against Pseudomonas aeruginosa and Enterococcus faecalis in an in vitro bladder model simulating human urinary concentrations after oral administration
23. Levofloxacin
24. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections
25. A multi-center randomized study comparing the efficacy and safety of IV and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia
26. A combined analysis of two studies comparing levofloxacin with two other fluoroquinolones for the treatment of acute pyelonephritis
27. Multi-center, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbation of chronic bronchitis
28. A multicenter, double-blind, randomized study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections
29. Levofloxacin, a second-generation fluoroquinolone
30. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy
31. Phototoxic potential of the new quinolone antibacterial agent levofloxacin in mice
32. Fluoroquinolone toxicity profiles: A review focusing on newer agents
33. A comparison of levofloxacin and ciprofloxacin for the treatment of complicated urinary tract infections
34. Levofloxacin versus ciprofloxacin versus lemofloxacin in acute pyelonephritis
35. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection
36. Enoxacin: A reappraisal of its clinical efficacy in the treatment of genitourinary tract infections
37. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens
38. Economic aspects of antibacterial adverse effects
39. Comparison of enoxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with complicated urinary tract infection
40. Enoxacin relieves symptoms of recurrent urinary infections more rapidly than cefuroxime axetil
41. Prevention of subsequent urinary tract infections in women by the use of anti-adherence antimicrobial agents: A double-blind comparison of enoxacin with co-trimoxazole
42. Treatment of uncomplicated recurrent cystitis in women: Lomefloxacin versus norfloxacin
43. Tolerability of fluoroquinolone antibiotics. Past, present and future
44. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands
45. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections
46. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose
47. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis
48. Review of norfloxacin in lower urinary tract infections
49. Treatment of recurrent urinary tract infections with norfloxacin versus trimethoprim-sulfamethoxazole
50. Norfloxacin vs pivmecillinam in the treatment of uncomplicated lower urinary tract infections in hospitalized elderly patients
51. Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections
52. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients
53. Analysis of the bacterial strains isolated from urine samples of hospitalized and ambulatory patients
54. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women
55. Ofloxacin for the treatment of urinary tract infections and biofilms in spinal cord injury
56. Treatments of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi-Center UUTI Study Group
57. Central nervous system toxicity of quinolones: Human and animal findings
58. Survey on antibiotic usage in the treatment of urinary tract infections
59. Levofloxacin and warfarin interaction
60. Drug-drug interactions with fluoroquinolones